Insider buying slowed for the second week in a row based on the number of companies with purchase records. It could be that geopolitical concerns are overriding economic news showing modest expansion.
Whatever the reason, we'd prefer to see boardroom confidence rising along with consumer confidence. They appear to be headed in opposite directions at the moment as consumer confidence is at a six year high according to the Conference Board's index.
Well, at least one CEO is showing confidence in her company. �Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ:ULTA) Chief Executive Officer, Marry Dillon bought 5,000 shares on the open market, just like you buy stock. She paid $97.35 per share for a total investment of $486,750.
[Related -Ulta Salon, Cosmetics & Fragrance, Inc. (ULTA): Bullish Options Play Eyes Further Upside in Ulta]
Top 10 Paper Companies To Own In Right Now: MEDL Mobile Holdings Inc (MEDL)
MEDL Mobile Holdings, Inc. incorporated on May 22, 2008 is a developer, incubator, marketer and aggregator of mobile application software (Apps). The Company is engaged in the monetization of mobile application software through four revenue generating platforms: development of customized Apps for third parties to monetize their particular intellectual property, persona or brand, incubation of Apps in partnership with third parties and from a library of more than 75,000 original Apps concept submissions, sale of advertising and sponsorship opportunities directly to brands via mobile advertising networks and acquisition of Apps from other developers and use of a application programming interface ( API).
The Company develops Apps for customers that vary in size from small start-ups to large multinational corporations, in a range of industries including retailing, fast food, air travel, medical devices, higher education and fashion. As of December 31, 2011, revenues its custom development accounted for approximately 93% of its total revenues. The Company prepares packages for sale in the Apple App Store and the Google Android Marketplace. This package includes app store copy, sample screen shots.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Digital Caddies Inc (OTCMKTS: CADY), MEDL Mobile Holdings Inc (OTCMKTS: MEDL) and Yappn Corp (OTCMKTS: YPPN) offer different ways to potentially profit from Internet or mobile technology. However, all three small cap stocks have also been the subject of paid promotions or investor relations types of activities. So will investors actually profit from the efforts of these small caps to profit from the Internet or mobile technology? Here is a quick reality check:
10 Best Diversified Bank Stocks To Buy For 2014: Fidia SpA (FDA)
Fidia SpA is an Italy-based company primarily engaged in the production of numerical controls and machine tools. The Company�� activities are divided into three main business lines. In the High-speed Milling Systems, it is involved in the production and sale of milling heads kits and cutting-edge equipment. Through the Numerical Controls, Dives and Software sector, it is active in the manufacture of numerical controls for milling systems, as well as in the development and distribution of computer-aided design (CAD) and computer-aided manufacturing (CAM) software. The After-sales Service sector includes the provision of technical services, sale of spare parts and scheduled maintenance contracts. The Company operates in Germany, France, Brazil, China, Poland and India, among others. Advisors' Opinion:- [By Patricio Kehoe]
Despite recent anti-tobacco laws passed by the European Union and the Food and Drug Administration (FDA) in the U.S, the company�� pricing power has helped maintain its margins. In 2012, for example, Phillip Morris hiked prices on its products in Russia, Germany, Belgium, Canada, France, Greece and Spain, among others. Although the necessary measure caused substantial volume declines in these countries, consumers rapidly became accustomed to the increased prices, and returned to their habitual product consumption. Given the success of this strategy, the firm is likely to rely on it in Japan for 2014, where taxes are expected to increase yet again by 8%, after the 40% spike in October 2010.
- [By Steven Silver]
Its Apremilast is currently under Food and Drug Administration (FDA) review for the anti-inflammatory condition, psoriatic arthritis, and has also shown promise in such indications as psoriasis and ankylosing spondylitis.
10 Best Diversified Bank Stocks To Buy For 2014: Medina International Holdings Inc (MIHI)
Medina International Holdings, Inc. (Medina), incorporated on June 23, 1998, manufactures products and services to assist emergency and defense organizations and personnel. The Company, through its two wholly owned subsidiaries, Harbor Guard Boats, Inc. (HGB) and Medina Marine, Inc. manufactures and sells recreational and commercial boats. The products are manufactured by HGB, which designs, manufactures, and markets hand-laid fiberglass and aluminum commercial boats ranging from 15 feet to 37 feet, which are utilized by fire, search and rescue, emergency, patrol, military and defense organizations. It manufactures commercial and recreational watercrafts.
As of April 30, 2012, HGB had nine models of commercial and recreational watercrafts. The Company�� products consist of commercial boats and recreational boats. As of April 30, 2012, Medina had seven commercial watercraft models, ranging from 15 feet to 37 feet in length. Its other watercraft includes 15 feet interceptor, which is used for rescue and fiber glass; 20-feet interceptor, which is used for fire rescue, rescue and fiber glass; 21 feet firecat, which is used for fire rescue, rescue and fiber glass; 24 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass; 26 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass; 30 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass, and 37 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass. As of April 30, 2012, the Company had two recreational watercraft models. Its watercraft products are made out of fiberglass and aluminum materials.
Advisors' Opinion:- [By Peter Graham]
Last Friday, small cap Digital Brand Media & Marketing Group Inc (OTCMKTS: DBMM) surged 22.22% while Blue Water Global Group Inc (OTCBB: BLUU) sank 18.42% and Medina International Holdings, Inc (OTCMKTS: MIHI) sank 50%. However, one of these small caps (Blue Water Global Group) appears to be reversing course in early morning trading today. So with it and the rest of these small cap stocks either sink or swim in trading this week? Here is a closer look to help you decide on an investing or trading strategy:
10 Best Diversified Bank Stocks To Buy For 2014: Point.360(PTSX)
Point.360 operates as an integrated media management services company in the United States. It offers film, video and audio post-production, archival, duplication, computer graphics, and data distribution services. The company also provides services to edit, master, reformat, covert, archive, and distribute its clients? film and video content, including television programming, feature films, and movie trailers. Its value-added services comprise visual effects, video and data editing, graphics and animation, digital color correction, picture restoration, audio post-production, audio restoration and layback, closed captioning and subtitling, foreign language mastering, standards conversion, broadcast encoding, global distribution and syndication, and archival services. In addition, Point.360 is involved in the rental and sale of DVDs and video games to consumers through its Movie>Q retail stores. Its customers include independent motion picture and television production com panies, television program suppliers, national television networks, infomercial providers, local television stations, television program syndicators, corporations, and educational institutions, as well as advertising agencies, and corporate or instructional video providers. The company is based in Burbank, California.
Advisors' Opinion:- [By Lisa Levin]
Point.360 (NASDAQ: PTSX) shares reached a new 52-week low of $0.528. Point.360's trailing-twelve-month ROE is -12.69%.
QC Holdings (NASDAQ: QCCO) shares tumbled 3.68% to reach a new 52-week low of $1.83. QC Holdings shares have dropped 42.60% over the past 52 weeks, while the S&P 500 index has gained 31.67% in the same period.
10 Best Diversified Bank Stocks To Buy For 2014: Aastrom Biosciences Inc.(ASTM)
Aastrom Biosciences, Inc., a regenerative medicine company, engages in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases. The company?s autologous expanded cellular therapy technology uses single-pass perfusion to produce human cell products for clinical use. Its clinical development programs include CLI program, which is in phase IIb clinical development for the treatment of serious and advanced stage of peripheral arterial diseases; and DCM development program, which is in Phase II for the treatment of dilated cardiomyopathy (DCM). The company also has two ongoing U.S. Phase II trials investigating surgical and catheter-based delivery for its product in the treatment of DCM. Aastrom Biosciences, Inc. was founded in 1989 and is headquartered in Ann Arbor, Michigan.
Advisors' Opinion:- [By John Udovich]
At the end of this week,�congressional scrutiny was weighting down large cap biotech Gilead Sciences, Inc (NASDAQ: GILD) and dragging down much of the biotech sector, but there was still good news surrounding small cap biotech stocks like Endocyte, Inc (NASDAQ: ECYT), Aastrom Biosciences Inc (NASDAQ: ASTM)�and TNI BioTech (OTCMKTS: TNIB) plus there were more biotech IPOs which debuted:
- [By Roberto Pedone]
Another under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Aastrom Biosciences (ASTM), which is a regenerative medicine company focused on the development of cell therapies to repair or regenerate damaged or diseased tissues. This stock has trended modestly lower over the last three months, with shares off by 4.9%.
If you take a look at the chart for Aastrom Biosciences, you'll notice that this stock just recently formed a double bottom chart pattern at $3.16 to $3.14 a share over the last month and change. Following that bottom, shares of ASTM have started to spike higher and move back above its 50-day moving average of $3.58 a share. That move is quickly pushing shares of ASTM within range of triggering a big breakout trade.
Market players should now look for long-biased trades in ASTM if it manages to break out above some near-term overhead resistance at $4.50 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 140,540 shares. If that breakout hits soon, then ASTM will set up to re-test or possibly take out its next major overhead resistance levels at $6.25 to $6.80 a share. Any high-volume move above those levels will then give ASTM a chance to re-fill some of its previous gap-down-zone from last August that started at $12 a share.
Traders can look to buy ASTM off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $3.58 a share. One can also buy ASTM off strength once it starts to clear $4.50 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By James E. Brumley]
With just a quick glance, Aastrom Biosciences Inc. (NASDAQ:ASTM) doesn't look like any less of a disaster today than it did a week ago, a month ago, or even a year ago. But, the longer you look at ASTM, the more it seems it may have already hit its ultimate bottom, and is now biding its time to start the rebound.
10 Best Diversified Bank Stocks To Buy For 2014: Soditech Ingenierie SA (SEC)
Soditech Ingenierie SA is a France-based company that is primarily engaged in electronic and mechanical engineering services in various sectors. The Company�� activity is organized into three sectors: Defense & Research, Space and Energy & Nuclear. It provides specialized services in four fields: aerospace, covering communication satellites, observation satellites and space stations; automotive, providing such services as engine design and plasturgy for equipment manufacturers; aeronautics, offering structural research for aircraft makers, instruments or electro-mechanical systems for assisting pilots and others, and defense, providing engineering of numerous tests and trials systems, with or without implementations, among others. The Company also offers additional services, such as energy forecasting and environmental analysis, environmental management system, and others. In May 2014, it restructured company into three main divisions: Defense & Research, Space and Energy & Nuclear. Advisors' Opinion:- [By Patricio Kehoe]
Over the past days hedge funds have been filing their form 13-F, which is a quarterly report of equity holdings filed by institutional investment managers with at least $100 million in equity assets under management, as required by the U.S. Securities and Exchange Commission (SEC). In this article, let麓s concentrate in one particular hedge fund and try to see the principal holdings in its portfolio. I will look into Citadel Advisor LLC from Kenneth C. Griffin, a Chicago-based investment firm.
- [By muhammadbazil]
In the past, hedge funds provided investors with a way to invest large amounts of money without much government regulation. In the past few years, government scrutiny into hedge funds has increased enormously. As a result, some of America�� largest hedge funds have opted to shrink away from the powers that be by becoming ��amily offices.��But, even in the face of increased federal oversight, there are some entities that are doing just the opposite. Indeed, some family offices are bucking the trend by becoming hedge funds that can seek out new clientele and invest with a wide range of investor capital.The more common move to shift from hedge fund to closed family office was popularized by large hedge funds and hedge fund managers like George Soros (Trades, Portfolio), Carl Icahn (Trades, Portfolio), and Steve Cohen�� SAC Capital Advisors (now Point72 Asset Management). Some estimates suggest that there are over 1,000 different family offices throughout the nation. The Dodd-Frank Act went into full effect in 2010, causing many hedge fund managers to rethink their positions.Going Against the TrendSeveral family offices are going against the trend by becoming hedge funds fully open to new investors. Although popular discourse has suggested that this is a negative move, many family-office-to-hedge-fund conversions are based on sound business planning.The legitimacy of switching from a hedge fund to a family office is generally only applicable in situations where the hedge fund manager controls extensive capital. For instance, George Soros (Trades, Portfolio) was able to start his family office with a hefty $24 billion to invest. Of course, as a family office, the Soros Fund Management LLC cannot solicit outside investors or manage any money that does not belong to the Soros family.For family offices that do not have $24 billion in capital to work with, remaining in business as a family office limits their investment options. Thus, the small undercurrent of fa
10 Best Diversified Bank Stocks To Buy For 2014: Hyperion Therapeutics Inc (HPTX)
Hyperion Therapeutics, Inc. (Hyperion), incorporated in November 2006, is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. The Company develops Ravicti (glycerol phenylbutyrate) to treat the prevalent urea cycle disorders (UCD) and hepatic encephalopathy (HE). The Company has completed two Phase II trials and one pivotal Phase III trial of Ravicti. The Company�� HE clinical program consists of two trials, which have enrolled patients with cirrhosis. On December 23, 2011, the Company submitted a new drug application (NDA) for Ravicti for the chronic management of UCD in patients aged six years and above based on data from its pivotal Phase III trial in adult patients and the results of two Phase II trials, one in adults and one in pediatric patients aged 6 through 17 years. In June 2013, Hyperion Therapeutics Inc announced that the completion of its acquisition of BUPHENYL (sodium phenylbutyrate) Tablets and Powder from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International, Inc.
In June 2011, the Company completed a 24-month carcinogenicity study of Ravicti in rats. On March 22, 2012, pursuant to an asset purchase agreement (purchase agreement) with Ucyclyd Pharma, Inc., a wholly owned subsidiary of Medicis Pharmaceutical Corporation, the Company purchased all of the worldwide rights to Ravicti. The Company also has an option to acquire all of Ucyclyd�� worldwide rights in BUPHENYL and AMMONUL (sodium phenylacetate and sodium benzoate) injection.
The Company conducted a pivotal Phase III trial of Ravicti in adult patients 18 years of age or older with UCD. The Company completed a second Phase II trial at five centers in North America in UCD patients aged 6 through 17 years. This trial includes two phases: a two-week, open-label, safety, tolerability, pharmacokinetic characteristics and ammonia control of Ravicti. The Co! mpany enrolled 77 adult and pediatric UCD patients in its two 12-month open-label safety studies, 69 of whom completed the studies. The Company conducted nonclinical genotoxicity and carcinogenicity studies to assess the tumorigenic potential of Ravicti in animals and to assess the relevant risk in humans. The Company is conducting a Phase II multi-center study of patients with cirrhosis and episodic HE.
Advisors' Opinion:- [By Sean Williams]
What: Shares of Hyperion Therapeutics (NASDAQ: HPTX ) , a biopharmaceutical company focused on treatments for orphan diseases and hepatology, rose as much as 10% after receiving orphan drug exclusivity status for Ravicti from the Food and Drug Administration, and exercising an option to acquire two additional urea cycle drugs from Valeant Pharmaceuticals (NYSE: VRX ) .
- [By Jesse Solomon]
NPS Pharmaceuticals (NPSP), for example, created a drug for treating short bowel syndrome. And Hyperion Therapeutics (HPTX) is developing a drug for hepatic encephalopathy, a decline of brain function that according to the National Institute of Health occurs when the liver is no longer able to remove toxins from the blood. Those stocks are up 20% and 40%, respectively, this year.
No comments:
Post a Comment